On the public citation graph

PARP inhibitors in ovarian cancer: An overview of the practice‐changing trials

0 signed · 131 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/emmm.200900041openalex-snapshot
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
inferredcites →https://doi.org/10.1007/s11912-020-0873-4openalex-snapshot
PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
inferredcites →https://doi.org/10.1016/j.annonc.2020.08.2102openalex-snapshot
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
inferredcites →https://doi.org/10.1016/j.annonc.2020.08.950openalex-snapshot
811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1
inferredcites →https://doi.org/10.1016/j.cell.2006.11.042openalex-snapshot
Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity
inferredcites →https://doi.org/10.1016/j.ygyno.2014.02.039openalex-snapshot
PARP inhibitors in ovarian cancer: Current status and future promise
inferredcites →https://doi.org/10.1016/j.ygyno.2015.03.042openalex-snapshot
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
inferredcites →https://doi.org/10.1016/j.ygyno.2015.12.020openalex-snapshot
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
inferredcites →https://doi.org/10.1016/j.ygyno.2019.08.010openalex-snapshot
PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib
inferredcites →https://doi.org/10.1016/s0140-6736(10)60893-8openalex-snapshot
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
inferredcites →https://doi.org/10.1016/s0140-6736(17)32440-6openalex-snapshot
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(11)70214-5openalex-snapshot
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
inferredcites →https://doi.org/10.1016/s1470-2045(14)70391-2openalex-snapshot
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
inferredcites →https://doi.org/10.1016/s1470-2045(16)30376-xopenalex-snapshot
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30559-9openalex-snapshot
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(19)30515-7openalex-snapshot
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
inferredcites →https://doi.org/10.1038/nature03445openalex-snapshot
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
inferredcites →https://doi.org/10.1038/nature12113openalex-snapshot
Integrated genomic characterization of endometrial carcinoma
inferredcites →https://doi.org/10.1038/nrclinonc.2016.191openalex-snapshot
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
inferredcites →https://doi.org/10.1038/s41416-018-0271-yopenalex-snapshot
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
inferredcites →https://doi.org/10.1038/s41571-020-0335-9openalex-snapshot
First-line PARP inhibition in ovarian cancer — standard of care for all?
inferredcites →https://doi.org/10.1038/s41598-017-13232-3openalex-snapshot
Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property
inferredcites →https://doi.org/10.1056/nejmoa0900212openalex-snapshot
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
inferredcites →https://doi.org/10.1056/nejmoa1103799openalex-snapshot
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
inferredcites →https://doi.org/10.1056/nejmoa1104390openalex-snapshot
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
inferredcites →https://doi.org/10.1056/nejmoa1105535openalex-snapshot
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
inferredcites →https://doi.org/10.1056/nejmoa1611310openalex-snapshot
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
inferredcites →https://doi.org/10.1056/nejmoa1810858openalex-snapshot
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
inferredcites →https://doi.org/10.1056/nejmoa1909707openalex-snapshot
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
inferredcites →https://doi.org/10.1056/nejmoa1910962openalex-snapshot
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
inferredcites →https://doi.org/10.1056/nejmoa1911361openalex-snapshot
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
inferredcites →https://doi.org/10.1093/annonc/mdt333openalex-snapshot
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
inferredcites →https://doi.org/10.1093/annonc/mdw374.49openalex-snapshot
ENDOLA : A GINECO-GINEGEPS French NCI sponsored phase I/II trial to assess the safety and efficacy of metronomic cyclophosphamide, metformin and OLAparib in recurrent advanced/metastatic ENDometrial cancer patients
inferredcites →https://doi.org/10.1093/annonc/mdw635openalex-snapshot
A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)
inferredcites →https://doi.org/10.1093/annonc/mdy157openalex-snapshot
Corrections to “Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
inferredcites →https://doi.org/10.1093/annonc/mdz018openalex-snapshot
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
inferredcites →https://doi.org/10.1093/annonc/mdz250.037openalex-snapshot
Response to pegylated liposomal doxorubicin (PLD) and weekly paclitaxel (wpac) in platinum resistant (PR) ovarian cancer (OC) by BRCA mutation status
inferredcites →https://doi.org/10.1136/esmoopen-2020-001110openalex-snapshot
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
inferredcites →https://doi.org/10.1136/ijgc-2020-igcs.18openalex-snapshot
18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial
inferredcites →https://doi.org/10.1146/annurev-med-050913-022545openalex-snapshot
Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
inferredcites →https://doi.org/10.1158/0008-5472.can-05-2119openalex-snapshot
Hypoxia-Induced Down-regulation of BRCA1 Expression by E2Fs
inferredcites →https://doi.org/10.1158/1078-0432.ccr-15-0887openalex-snapshot
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
inferredcites →https://doi.org/10.1158/2159-8290.cd-15-0714openalex-snapshot
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
inferredcites →https://doi.org/10.1177/1758835919849753openalex-snapshot
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
inferredcites →https://doi.org/10.1186/s12885-017-3981-2openalex-snapshot
Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
inferredcites →https://doi.org/10.1200/jco.19.02745openalex-snapshot
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
inferredcites →https://doi.org/10.1200/jco.2008.16.0812openalex-snapshot
A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
inferredcites →https://doi.org/10.1200/jco.2009.26.9589openalex-snapshot
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
inferredcites →https://doi.org/10.1200/jco.2011.36.9215openalex-snapshot
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
inferredcites →https://doi.org/10.1200/jco.2014.56.2728openalex-snapshot
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
inferredcites →https://doi.org/10.1200/jco.2015.33.15_suppl.tps5607openalex-snapshot
ENGOT-OV24-NSGO/AVANOVA: Niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
inferredcites →https://doi.org/10.1200/jco.2020.38.15_suppl.1586openalex-snapshot
Comparison of genomic instability test scores used for predicting PARP activity in ovarian cancer.
inferredcites →https://doi.org/10.1200/jco.2020.38.15_suppl.6002openalex-snapshot
Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
inferredcites →https://doi.org/10.1200/jco.2020.38.15_suppl.6003openalex-snapshot
A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.
inferredcites →https://doi.org/10.1200/jco.2020.38.15_suppl.6050openalex-snapshot
Evaluation of an individualized starting-dose of niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.
inferredcites →https://doi.org/10.17615/hvp3-wg08openalex-snapshot
Integrated genomic analyses of ovarian carcinoma
inferredcites →https://doi.org/10.18632/oncotarget.7277openalex-snapshot
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
inferredcites →https://doi.org/10.2147/cmar.s221001openalex-snapshot
PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
inferredcites →https://doi.org/10.31525/ct1-nct03968406openalex-snapshot
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
inferredcites →https://doi.org/10.31525/ct1-nct04080284openalex-snapshot
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
inferredcites →https://doi.org/10.3322/caac.21492openalex-snapshot
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.5066556openalex-extracted
Simplified Maxwell-Boltzmann-Hansch Function (SMBH function) and its Application in PROTAC
inferred← citeshttps://doi.org/10.1002/1878-0261.13710openalex-snapshot
Cell‐free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer
inferred← citeshttps://doi.org/10.1002/2211-5463.13572openalex-snapshot
Nuclear endonuclease G controls cell proliferation in ovarian cancer
inferred← citeshttps://doi.org/10.1002/gcc.22939openalex-snapshot
Homologous recombination repair deficiency (HRD): From biology to clinical exploitation
inferred← citeshttps://doi.org/10.1002/jlcr.4135openalex-snapshot
Current Advances in PARP1‐Targeted Theranostics
inferred← citeshttps://doi.org/10.1007/s00066-023-02122-5openalex-snapshot
DNA as the main target in radiotherapy—a historical overview from first isolation to anti-tumour immune response
inferred← citeshttps://doi.org/10.1007/s00292-021-00953-6openalex-snapshot
[Next generation sequencing in histopathology : Applications and methodological challenges].
inferred← citeshttps://doi.org/10.1007/s00432-023-04811-1openalex-snapshot
Apatinib combined with olaparib induces ferroptosis via a p53-dependent manner in ovarian cancer
inferred← citeshttps://doi.org/10.1007/s10549-023-06995-zopenalex-snapshot
DNA repair pathways in breast cancer: from mechanisms to clinical applications
inferred← citeshttps://doi.org/10.1007/s10549-023-07046-3openalex-snapshot
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes
inferred← citeshttps://doi.org/10.1007/s11033-024-09357-0openalex-snapshot
MiRNAs related in signaling pathways of women’s reproductive diseases: an overview
inferred← citeshttps://doi.org/10.1007/s12672-024-01497-wopenalex-snapshot
Circ_0001068 accelerates the development of ovarian cancer by promoting FXYD5 expression through inhibiting mir-149-5p activity
inferred← citeshttps://doi.org/10.1007/s13193-022-01683-8openalex-snapshot
Extrapelvic Endometriosis Mimicking Peritoneal Surface Malignancy: Case Report and a Review of Literature
inferred← citeshttps://doi.org/10.1007/s40944-025-00964-8openalex-snapshot
Predictive and Prognostic Factors in Epithelial Ovarian Cancer: A Review
inferred← citeshttps://doi.org/10.1016/b978-3-437-21207-9.00020-3openalex-snapshot
Gynäkologische Tumoren
inferred← citeshttps://doi.org/10.1016/j.bioorg.2025.108188openalex-snapshot
Role of PARP-1 structural and functional features in PARP-1 inhibitors development
inferred← citeshttps://doi.org/10.1016/j.cbi.2024.110958openalex-snapshot
CRABP2 reduces the sensitivity of Olaparib in ovarian cancer by downregulating Caspase-8 and decreasing the production of reactive oxygen species
inferred← citeshttps://doi.org/10.1016/j.ejmech.2021.114094openalex-snapshot
Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities
inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116405openalex-snapshot
High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.117926openalex-snapshot
Mitochondrial-targeted iridium(III) complexes suppress tumor growth through inducting immunogenic cell death to activate immune response
inferred← citeshttps://doi.org/10.1016/j.ejphar.2025.178298openalex-snapshot
PARPs in tumor immunology: Signal transduction and combination therapy for the future
inferred← citeshttps://doi.org/10.1016/j.esmoop.2021.100238openalex-snapshot
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey
inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e38888openalex-snapshot
Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.jmoldx.2023.01.003openalex-snapshot
Pyrosequencing Assay for BRCA1 Methylation Analysis
inferred← citeshttps://doi.org/10.1016/j.saa.2023.123074openalex-snapshot
Spectroscopic investigations, quantum chemical, drug likeness and molecular docking studies of methyl 1-methyl-4-nitro-pyrrole-2-carboxylate: A novel ovarian cancer drug
inferred← citeshttps://doi.org/10.1016/j.ygyno.2023.01.020openalex-snapshot
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
inferred← citeshttps://doi.org/10.1016/j.ygyno.2023.03.016openalex-snapshot
Outcomes of the "BRCA Quality Improvement Dissemination Program": An initiative to improve patient receipt of cancer genetics services at five health systems
inferred← citeshttps://doi.org/10.1016/j.ygyno.2026.06.011openalex-snapshot
The real-world utility of homologous repair deficiency testing in BRCA1/2 wild-type high-grade serous carcinoma and the utility of MYC amplification as a potential surrogate marker
inferred← citeshttps://doi.org/10.1017/erm.2023.3openalex-snapshot
Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.5c01170openalex-snapshot
Precision-Oriented Theophylline-Platinum(IV) Prodrugs: Eliciting Synthetic Lethality in BRCA1-Deficient Ovarian Cancer with Enhanced Efficacy and Reduced Toxicity In Vitro and In Vivo
inferred← citeshttps://doi.org/10.1038/s41568-024-00781-9openalex-snapshot
Tumour hypoxia in driving genomic instability and tumour evolution
inferred← citeshttps://doi.org/10.1038/s41698-024-00640-8openalex-snapshot
Spatial tumor immune microenvironment phenotypes in ovarian cancer
inferred← citeshttps://doi.org/10.1038/s42003-025-08836-9openalex-snapshot
Long non-coding RNAs as a biomarker for homologous recombination deficiency and parp inhibitor sensitivity in high-grade serous ovarian cancers
inferred← citeshttps://doi.org/10.1080/0284186x.2022.2140015openalex-snapshot
Societal costs of ovarian cancer in a population-based cohort – a cost of illness analysis
inferred← citeshttps://doi.org/10.1080/07357907.2021.1973021openalex-snapshot
Platinum-Pemetrexed Chemotherapy for Recurrent Ovarian Cancer (ROC): A Single Center Experience
inferred← citeshttps://doi.org/10.1080/14728214.2023.2218643openalex-snapshot
Emerging peptide therapeutics for the treatment of ovarian cancer
inferred← citeshttps://doi.org/10.1111/bcp.15015openalex-snapshot
Identification of different side effects between PARP inhibitors and their polypharmacological multi‐target rationale
inferred← citeshttps://doi.org/10.1111/fcp.12834openalex-snapshot
Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers
inferred← citeshttps://doi.org/10.1111/vco.13053openalex-snapshot
The Poly ( ADP ‐Ribose) Polymerase‐1 Enzyme Is Overexpressed in Various Solid Canine Tumours: An Immunohistochemical Study
inferred← citeshttps://doi.org/10.1158/2767-9764.crc-24-0001openalex-snapshot
Nucleolar Localization of the RNA Helicase DDX21 Predicts Survival Outcomes in Gynecologic Cancers
inferred← citeshttps://doi.org/10.1159/000521840openalex-snapshot
BRCA1 Mutation: An Insidious Enemy with Multiple Facets…
inferred← citeshttps://doi.org/10.1159/000525029openalex-snapshot
Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity
inferred← citeshttps://doi.org/10.1186/s13048-021-00830-zopenalex-snapshot
CACNA1C is a prognostic predictor for patients with ovarian cancer
inferred← citeshttps://doi.org/10.1200/edbk_350232openalex-snapshot
Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects
inferred← citeshttps://doi.org/10.1200/po-24-00825openalex-snapshot
Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer
inferred← citeshttps://doi.org/10.1200/po.22.00555openalex-snapshot
Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2540583/v1openalex-snapshot
Combination of olaparib and savolitinib overcomes olaparib-resistance in epithelial ovarian cancer models
inferred← citeshttps://doi.org/10.21203/rs.3.rs-3426005/v1openalex-snapshot
Targeting PARP1 actives cGAS-STING signaling pathway to promote tumor cells apoptosis and reshape tumor immune microenvironment in non-small cell lung cancer
inferred← citeshttps://doi.org/10.2139/ssrn.5222097openalex-snapshot
Mitochondrial-Targeted Iridium(Iii) Complexes Suppress Tumor Growth Through Inducting Immunogenic Cell Death to Activate Immune Response
inferred← citeshttps://doi.org/10.2967/jnumed.123.265418openalex-snapshot
Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy
inferred← citeshttps://doi.org/10.33590/emjoncol/10300067openalex-snapshot
A Review of the Latest Advancements in Ovarian Cancer Care Featured at ESMO 2022
inferred← citeshttps://doi.org/10.3389/fgene.2021.674094openalex-snapshot
Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions
inferred← citeshttps://doi.org/10.3389/fmolb.2021.762741openalex-snapshot
Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer
inferred← citeshttps://doi.org/10.3389/fonc.2022.998388openalex-snapshot
Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation
inferred← citeshttps://doi.org/10.3390/cancers13102386openalex-snapshot
Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer—Current Use and Future Opportunities
inferred← citeshttps://doi.org/10.3390/cancers14041098openalex-snapshot
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives
inferred← citeshttps://doi.org/10.3390/cancers14051132openalex-snapshot
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations
inferred← citeshttps://doi.org/10.3390/cancers14143404openalex-snapshot
Extracellular Vesicles-ceRNAs as Ovarian Cancer Biomarkers: Looking into circRNA-miRNA-mRNA Code
inferred← citeshttps://doi.org/10.3390/cancers14194621openalex-snapshot
Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival
inferred← citeshttps://doi.org/10.3390/cancers14194649openalex-snapshot
Using Patient-Derived Xenograft (PDX) Models as a ‘Black Box’ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial
inferred← citeshttps://doi.org/10.3390/cancers14236010openalex-snapshot
Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes
inferred← citeshttps://doi.org/10.3390/cells10092434openalex-snapshot
Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status
inferred← citeshttps://doi.org/10.3390/ijms22168506openalex-snapshot
PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
inferred← citeshttps://doi.org/10.3390/ijms24032292openalex-snapshot
Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens
inferred← citeshttps://doi.org/10.3390/ijms242417467openalex-snapshot
Assessing the Phenotype of a Homologous Recombination Deficiency Using High Resolution Array-Based Comparative Genome Hybridization in Ovarian Cancer
inferred← citeshttps://doi.org/10.3390/ijtm4030031openalex-snapshot
Targeting Cancer Stem Cells with Radioimmunotherapy: The Case of the Ovarian Cancer Stemness-Associated Biomarker L1CAM
inferred← citeshttps://doi.org/10.3802/jgo.2021.32.e34openalex-snapshot
Current status and future directions of ovarian cancer prognostic models
inferred← citeshttps://doi.org/10.5281/zenodo.6997707openalex-snapshot
CXCL10 and CCL5 as feasible Biomarkers for Immunotherapy of Homologous Recombination Deficient Ovarian Cancer
inferred← citeshttps://doi.org/10.56782/pps.185openalex-snapshot
PARP inhibitors in ovarian cancer therapy
inferred← citeshttps://doi.org/10.70675/ab8b1f5az3c15z4b5fzba28z247b40b8c7e0openalex-snapshot
Translational control in ovarian cancer : role of the glutaminyl-tRNA synthetase QARS in DNA damage response
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.